CTLA4 and colorectal carcinoma: Another study demonstrated the capacity of capecitabine, a chemotherapeutic agent, to downregulate CTLA4 expression on CRC (colorectal cancer) tissues, shedding light on its immunomodulatory capacity in addition to its previously known disruption of DNA synthesis [84].